Roche: study in lung cancer fails and is discontinued

(CercleFinance.com) - Roche announces the failure of its phase II/III SKYSCRAPER-06 study, evaluating tiragolumab in combination with Tecentriq and chemotherapy, as a first-line treatment for metastatic non-squamous non-small cell lung cancer.


While safety was consistent with previous studies, SKYSCRAPER-06 failed to meet the primary endpoints of progression-free survival in the primary analysis and overall survival in the first interim analysis.

The combination showed reduced efficacy compared to the comparator group, leading the Swiss healthcare group to discontinue this trial. It will evaluate any relevant changes required to the ongoing tiragolumab program.

Copyright (c) 2024 CercleFinance.com. All rights reserved.